{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:41:00Z","timestamp":1791484860783,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jaad.2025.06.006","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T12:21:59Z","timestamp":1752582119000},"page":"937-945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial"],"prefix":"10.1016","volume":"93","author":[{"given":"Anubha","family":"Dev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-4988","authenticated-orcid":false,"given":"Keshavamurthy","family":"Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Bishnoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu Sendhil","family":"Kumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitaishi","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Parsad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.06.006_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1477-7525-1-58","article-title":"Quality of life in patients with vitiligo","volume":"1","author":"Parsad","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"10.1016\/j.jaad.2025.06.006_bib2","first-page":"365","article-title":"S1 Guideline: diagnosis and therapy of vitiligo","volume":"20","author":"B\u00f6hm","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"10.1016\/j.jaad.2025.06.006_bib3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.06.006_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15821","article-title":"Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice","volume":"35","author":"Song","year":"2022","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2025.06.006_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/phpp.12661","article-title":"Evaluation of low-dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: a pilot study","volume":"37","author":"Fang","year":"2021","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"4","key":"10.1016\/j.jaad.2025.06.006_bib6","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open label pilot study of 2% tofacitinib for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.06.006_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","article-title":"A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo","volume":"81","author":"McKesey","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.06.006_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.06.006_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.06.006_bib10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaad.2016.12.040","article-title":"Clinical markers of vitiligo activity","volume":"76","author":"Benzekri","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.06.006_bib11","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","article-title":"Development and validation of the vitiligo extent score (VES): an International Collaborative Initiative","volume":"136","author":"van Geel","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.006_bib12","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jaad.2012.01.038","article-title":"Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL)","volume":"69","author":"Lilly","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.06.006_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2310\/7750.2013.12053","article-title":"Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo","volume":"17","author":"Kanwar","year":"2013","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.jaad.2025.06.006_bib14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1067\/mjd.2001.113475","article-title":"Oral dexamethasone pulse treatment for vitiligo","volume":"44","author":"Radakovic-Fijan","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.06.006_bib15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-4362.1993.tb02754.x","article-title":"Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease","volume":"32","author":"Pasricha","year":"1993","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.06.006_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4103\/0378-6323.42905","article-title":"An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad\/narrow band UVB phototherapy in progressive vitiligo","volume":"74","author":"Rath","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"7","key":"10.1016\/j.jaad.2025.06.006_bib17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/ijd.15464","article-title":"Oral mini-pulse therapy in vitiligo: a systematic review","volume":"60","author":"Chavez-Alvarez","year":"2021","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.006_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatol Treat"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.006_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/pigmentinternational.pigmentinternational_38_22","article-title":"To study the role of tofacitinib and betamethasone pulse in the treatment of vitiligo at a tertiary care centre: an observational comparative study","volume":"11","author":"Singh","year":"2024","journal-title":"Pigment Int"},{"issue":"11","key":"10.1016\/j.jaad.2025.06.006_bib20","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm","volume":"37","author":"van Geel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.06.006_bib21","series-title":"Vitiligo","first-page":"123","article-title":"Immunomodulators and immunosuppressives in vitiligo treatment","author":"Bishnoi","year":"2018"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.006_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3889\/oamjms.2018.042","article-title":"Micro - focused phototherapy associated to janus kinase inhibitor: a promising valid therapeutic option for patients with localized vitiligo","volume":"6","author":"Gianfaldoni","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.jaad.2025.06.006_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jdin.2022.09.003","article-title":"Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: an evidence-based review","volume":"9","author":"Abduelmula","year":"2022","journal-title":"JAAD Int"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225022418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225022418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:22:52Z","timestamp":1758198172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225022418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0190962225022418"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.06.006","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}